Collecting endometrial cancer samples to test PARP inhibitors
Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
This study is trying to see how well PARP inhibitors might work for people with localized endometrial cancer by collecting their tumor and blood samples to create models for testing.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 16 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Francois Baclesse Academic / other |
| Locations | 1 site (Caen) |
| Trial ID | NCT06603506 on ClinicalTrials.gov |
What this trial studies
This observational study involves three stages: first, the collection of tumor and blood samples from patients with localized endometrial cancer. Next, organoid models will be created from these tumor samples. Finally, functional tests will be developed to predict how well patients may respond to PARP inhibitor treatments based on their organoid responses.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with localized endometrial cancer who are candidates for surgical treatment.
Not a fit: Patients with other active cancers or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with endometrial cancer.
How similar studies have performed: While this approach is innovative, similar studies using organoids for cancer treatment prediction have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 years or more * Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment. * Patient with localized endometrial cancer, presenting: * A high-grade endometrioid histological type and/or * P53 mutation and/or * a non-endometrioid histological type regardless of P53 status. * Patient affiliated to a social security scheme * Information and signature of informed consent prior to any specific study procedure Exclusion Criteria: * Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin). * Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Where this trial is running
Caen
- Centre François Baclesse — Caen, France (Recruiting)
Study contacts
- Study coordinator: Gwenn LE GALL, Medical Doctor
- Email: g.legall@baclesse.unicancer.fr
- Phone: +33231455050
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.